{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:49:57Z","timestamp":1789145397232,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hunan Natural Science Foundation of China","award":["No. S2023JJMSXM1512"],"award-info":[{"award-number":["No. S2023JJMSXM1512"]}]},{"name":"Hunan Natural Science Foundation of China","award":["No. S2023JJMSXM1512"],"award-info":[{"award-number":["No. S2023JJMSXM1512"]}]},{"name":"Hunan Natural Science Foundation of China","award":["No. S2023JJMSXM1512"],"award-info":[{"award-number":["No. S2023JJMSXM1512"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97591-2","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T16:47:01Z","timestamp":1744476421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The cost effectiveness of penpulimab with paclitaxel and carboplatin in first-line treatment of metastatic squamous non-small cell lung cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Kaiqi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"97591_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"97591_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen, P., Liu, Y., Wen, Y. & Zhou, C. Non-small cell lung cancer in China. Cancer Commun. (Lond). 42, 937\u2013970. https:\/\/doi.org\/10.1002\/cac2.12359 (2022).","journal-title":"Cancer Commun. (Lond)"},{"key":"97591_CR3","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma, N., Santana-Davila, R. & Molina, J. R. Non-Small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin. Proc. 94, 1623\u20131640. https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.013 (2019).","journal-title":"Mayo Clin. Proc."},{"key":"97591_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","volume":"72","author":"KD Miller","year":"2022","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J. Clin. 72, 409\u2013436. https:\/\/doi.org\/10.3322\/caac.21731 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"97591_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.annonc.2020.10.479","volume":"32","author":"M Shi","year":"2021","unstructured":"Shi, M. et al. Comparing nanoparticle polymeric micellar Paclitaxel and solvent-based Paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial. Ann. Oncol. 32, 85\u201396. https:\/\/doi.org\/10.1016\/j.annonc.2020.10.479 (2021).","journal-title":"Ann. Oncol."},{"key":"97591_CR6","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst, R. S. et al. Atezolizumab for First-Line treatment of PD-L1-Selected patients with NSCLC. N Engl. J. Med. 383, 1328\u20131339. https:\/\/doi.org\/10.1056\/NEJMoa1917346 (2020).","journal-title":"N Engl. J. Med."},{"key":"97591_CR7","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous Non-Small-Cell lung cancer. N Engl. J. Med. 379, 2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865 (2018).","journal-title":"N Engl. J. Med."},{"key":"97591_CR8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","volume":"17","author":"S Ren","year":"2022","unstructured":"Ren, S. et al. Camrelizumab plus carboplatin and Paclitaxel as First-Line treatment for advanced squamous NSCLC (CameL-Sq): A phase 3 trial. J. Thorac. Oncol. 17, 544\u2013557. https:\/\/doi.org\/10.1016\/j.jtho.2021.11.018 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"97591_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. Tislelizumab plus chemotherapy vs chemotherapy alone as First-line treatment for advanced squamous Non-Small-Cell lung cancer: A phase 3 randomized clinical trial. JAMA Oncol. 7, 709\u2013717. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0366 (2021).","journal-title":"JAMA Oncol."},{"key":"97591_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41392-024-01865-6","volume":"9","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study. Signal. Transduct. Target. Ther. 9, 148. https:\/\/doi.org\/10.1038\/s41392-024-01865-6 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"97591_CR11","unstructured":"Penpulimab monoclonal antibody (PD-1) obtains marketing approval in China. (2021)."},{"key":"97591_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(23)00431-9","volume":"12","author":"H Zhong","year":"2024","unstructured":"Zhong, H. et al. First-line penpulimab combined with Paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med. 12, 355\u2013365. https:\/\/doi.org\/10.1016\/S2213-2600(23)00431-9 (2024).","journal-title":"Lancet Respir Med."},{"key":"97591_CR13","unstructured":"Guidelines for the diagnosis and treatment of Non-small cell lung cancer by the Chinese society of clinical Oncology(CSCO). http:\/\/www.csco.org.cn (2024)."},{"key":"97591_CR14","unstructured":"National comprehensive cancer network clinical practice guidelines in oncology (NCCN guidelines):Non-Small Cell Lung Cancer,verson5. https:\/\/www.nccn.org\/guidelines (2024)."},{"key":"97591_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.6004\/jnccn.2020.7796","volume":"19","author":"D Ding","year":"2021","unstructured":"Ding, D. et al. Cost-Effectiveness analysis of durvalumab plus chemotherapy in the First-Line treatment of Extensive-Stage small cell lung cancer. J. Natl. Compr. Canc Netw. 19, 1141\u20131147. https:\/\/doi.org\/10.6004\/jnccn.2020.7796 (2021).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"97591_CR16","doi-asserted-by":"publisher","first-page":"1223020","DOI":"10.3389\/fimmu.2023.1223020","volume":"14","author":"G Xiang","year":"2023","unstructured":"Xiang, G. et al. Cost-effectiveness of Serplulimab as first-line therapy for extensive-stage small cell lung cancer in China. Front. Immunol. 14, 1223020. https:\/\/doi.org\/10.3389\/fimmu.2023.1223020 (2023).","journal-title":"Front. Immunol."},{"key":"97591_CR17","doi-asserted-by":"publisher","first-page":"1382088","DOI":"10.3389\/fimmu.2024.1382088","volume":"15","author":"H Zheng","year":"2024","unstructured":"Zheng, H., Zeng, Y., Wen, F. & Hu, M. Cost-effectiveness of additional Serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients. Front. Immunol. 15, 1382088. https:\/\/doi.org\/10.3389\/fimmu.2024.1382088 (2024).","journal-title":"Front. Immunol."},{"key":"97591_CR18","doi-asserted-by":"publisher","first-page":"1044678","DOI":"10.3389\/fimmu.2022.1044678","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y., Liu, K., Qin, Q. & Zhu, H. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis. Front. Immunol. 13, 1044678. https:\/\/doi.org\/10.3389\/fimmu.2022.1044678 (2022).","journal-title":"Front. Immunol."},{"key":"97591_CR19","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/hed.27452","volume":"45","author":"J Han","year":"2023","unstructured":"Han, J. et al. First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: an updated network meta-analysis and cost-effectiveness analysis. Head Neck 45, 2246\u20132258. https:\/\/doi.org\/10.1002\/hed.27452 (2023).","journal-title":"Head Neck"},{"key":"97591_CR20","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1007\/s12325-022-02101-9","volume":"39","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y., Liu, K., Ding, D., Zhou, Y. & Peng, L. Pembrolizumab plus chemotherapy as First-Line treatment for advanced esophageal cancer: A Cost-Effectiveness analysis. Adv. Ther. 39, 2614\u20132629. https:\/\/doi.org\/10.1007\/s12325-022-02101-9 (2022).","journal-title":"Adv. Ther."},{"key":"97591_CR21","doi-asserted-by":"publisher","first-page":"175628482312072","DOI":"10.1177\/17562848231207200","volume":"16","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y., Liu, K., Zhu, H. & Wu, H. Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric\/gastroesophageal junction cancer: a cost-effectiveness analysis. Th. Adv. Gastroenterol. 16, 17562848231207200. https:\/\/doi.org\/10.1177\/17562848231207200 (2023).","journal-title":"Th. Adv. Gastroenterol."},{"key":"97591_CR22","doi-asserted-by":"publisher","first-page":"e7070","DOI":"10.1002\/cam4.7070","volume":"13","author":"K Liu","year":"2024","unstructured":"Liu, K., Zhu, Y., Zhu, H. & Zeng, M. Combination tumor-treating fields treatment for patients with metastatic non-small cell lung cancer: A cost-effectiveness analysis. Cancer Med. 13, e7070. https:\/\/doi.org\/10.1002\/cam4.7070 (2024).","journal-title":"Cancer Med."},{"key":"97591_CR23","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.2147\/RMHP.S429394","volume":"16","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Zhang, H., Li, L. F., Feng, L. & Liu, Q. Cost-Effectiveness analysis of pembrolizumab plus chemotherapy in squamous Non-Small-Cell lung cancer in China. Risk Manag Healthc. Policy. 16, 1849\u20131857. https:\/\/doi.org\/10.2147\/RMHP.S429394 (2023).","journal-title":"Risk Manag Healthc. Policy"},{"key":"97591_CR24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s12325-024-02808-x","volume":"41","author":"F Li","year":"2024","unstructured":"Li, F., Chen, Y., Xiao, D., Jiang, S. & Yang, Y. Cost-Effectiveness analysis of sintilimab plus chemotherapy in advanced Non-Squamous Non-Small cell lung cancer: A societal perspective. Adv. Ther. 41, 1436\u20131449. https:\/\/doi.org\/10.1007\/s12325-024-02808-x (2024).","journal-title":"Adv. Ther."},{"key":"97591_CR25","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 22, 1081\u20131092. https:\/\/doi.org\/10.1016\/S1470-2045(21)00297-7 (2021).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97591-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97591-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97591-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:34:06Z","timestamp":1777386846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97591-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97591"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97591-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: In this article the grant number in the Funding information section was incorrectly given as \"No. S2023JJMSXM1512\" and is now corrected to read \"This work, including the journal's Rapid Service Fee, was supported by the Hunan Natural Science Foundation of China (No.2023JJ30886).\"","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12679"}}